Supplementary Figure S4 from Use of ctDNA in Older Women with ER+ Breast Cancer to Facilitate Surgical De-escalation: A Prospective, Hybrid-Decentralized Trial with Correlative Studies

<jats:p>&lt;p&gt;Supplementary Figure 4: (a) Magee Equations (https://path.upmc.edu/onlineTools/mageeequations.html) can be used to estimate the OncotypeDX Recurrence Score. Plot shows that there is no difference in Magee Equation score (based on the average Magee Equation score) between those patients who had baseline ctDNA positive and baseline ctDNA negative tumors. (b) Similar analysis showing the results for Magee Equation 3, which has been previously been shown to associate with response to endocrine therapy. The filled circles for a subset of patients in the ctDNA positive group indicate those who cleared their ctDNA after 6 months of endocrine therapy.&lt;/p&gt;</jats:p>